ARTICLE | Deals
EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs
July 23, 2020 2:10 AM UTC
The first disclosed deals for Alexis Borisy’s EQRx provide a glimpse of the targets and economics of its low-cost approach to drug development.
The company, which launched in January with $200 million, is using a mix of in-house drug discovery and in-licensing to build a pipeline of first- and next-in-class drug candidates launched at "radically lower" prices than commercial competitors, with the goal of bringing 10 drugs to market in the next 10 years (see “Borisy Newco Disrupting Biopharma Model”)...